Pharmacogenetics of cardiovascular drugs

Saleh, Ateka; Al-abcha, Abdullah; Pereira, Naveen L.

doi:10.1097/hco.0000000000001038

Cited by 2 publications

(2 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,6 As rehabilitation and leucine-rich amino acid supplements can increase muscle mass and strength, the early detection, diagnosis and treatment of sarcopenia are important for improving physical function. 7,8 The effects of statins on muscle health are controversial. Statins are a class of drugs that lower low-density lipoprotein cholesterol levels, and are the drugs of choice to reduce cardiovascular disease morbidity and mortality.…”

Section: Introductionmentioning

confidence: 99%

“…7 Although statins effectively lower cholesterol levels, they can also cause muscle-related sideeffects, such as muscle pain, weakness, myalgia, myopathy and rhabdomyolysis in up to one-third of statin users. 8 Mild myalgia appears in 5-10% of patients taking statins. 9 Severe muscle damage, also known as rhabdomyolysis, is a rare but serious side-effect of statins.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Matsumoto¹,

Yoshimura²,

Nagano³

et al. 2023

Geriatrics Gerontology Int

View full text Add to dashboard Cite

AimThe effects of statins on muscle health are not well established. Therefore, this study investigated the impact of statin use on muscle strength and mass recovery in patients with sarcopenia after stroke.MethodsThis retrospective cohort study included stroke patients with sarcopenia hospitalized between 2015 and 2021 at a post‐acute rehabilitation hospital. Sarcopenia was diagnosed using handgrip strength and skeletal muscle mass index measured using bioelectrical impedance analysis according to the 2019 criteria of the Asian Working Group for Sarcopenia. The study outcomes included handgrip strength and skeletal muscle mass index at hospital discharge. We used multivariate analyses to examine whether statin use was independently associated with the outcomes. Statistical significance was set at P < 0.05.ResultsOf the 586 patients enrolled, 241 (mean age 79.3 years, 44.4% men) presented with sarcopenia and were included in the analysis. Statin use was observed in 61 (25.3%) patients. Statin use was independently negatively associated with handgrip strength at discharge (β = −0.095, P = 0.032), but not with skeletal muscle mass index at discharge (β = 0.019, P = 0.692).ConclusionsStatin use was negatively associated with muscle strength recovery, but not with muscle mass in patients with sarcopenia who underwent rehabilitation after stroke. To maximize outcomes, sufficient consideration is needed for statin use in these patients. Geriatr Gerontol Int 2023; ••: ••–••.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Matsumoto¹,

Yoshimura²,

Nagano³

et al. 2023

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

Genetics in the diagnosis and treatment of cardiovascular diseases

Bliden,

Singh,

Shanoada

et al. 2024

J Transl Genet Genom

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) remain one of the leading causes of morbidity and mortality worldwide, with genetics being a major risk factor. Genetic cardiovascular disease can occur either because of single variant (Mendelian) or polygenic influences and has been linked to inherited cardiovascular conditions (ICC) such as arrhythmias, cardiomyopathies, dyslipidemias, and aortopathies which are significant factors leading to sudden cardiac death in young adults. Timely screening, diagnosis, and management of ICC can not only provide life-saving treatment to a patient, but also identify at-risk family members. The field of pharmacogenomics (PGx) helped to understand the variable action of medications such as clopidogrel, aspirin, warfarin, and statin according to genotype. Newer technologies such as multi-omics can combine data from multiple sources such as genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiome. These advancements can contribute to the development of polygenic prediction scores and precision medicine tailored to individual genotypes. Substantial strides have been made in genetic-based therapeutics, gene editing technologies, and drug delivery systems, which have significantly expanded treatment options for patients with acquired or inherited CVDs. Although variable, the country- and society-specific guidelines on genetic testing for ICC and PGx and treatment are being continuously updated to keep up with ongoing research in the field. Along with appropriate knowledge, other factors including cost and availability of genetic testing play a vital role in the usage by both physicians and patients. With the advent of newer genetic testing for CVDs, a key factor is the availability of genetic counselors (GCs) who are specifically trained in cardiovascular genomics. The current review provides a concise summary of the major influences of genetics in the diagnosis and treatment of CVDs.

show abstract

Pharmacogenetics of cardiovascular drugs

Cited by 2 publications

References 64 publications

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Statin use impairs muscle strength recovery in post‐stroke patients with sarcopenia

Genetics in the diagnosis and treatment of cardiovascular diseases

Contact Info

Product

Resources

About